Innovent Receives IND Approval to Initiate Clinical Trials in China with its anti-OX40 Agonistic Antibody IBI101 and its anti-RANKL Antibody IBI307 Jul 26, 2018 Life Science
I-Mab Out-Licenses Bi-Specific to South Korea’s ABL Bio in $100 Million Deal Jul 26, 2018 Life Science
KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma Jul 26, 2018 Life Science
Vivo Builds Five AI Institutes in China, the US; Chief Scientist Still Unknown Jul 26, 2018 Technology
